ClinicalTrials.gg
RecruitingNCT05747664Updated Apr 8, 2024

To Compare the Safety and PK/PD Characteristics of Subjects With Between Hepatic Impairment and Normal Hepatic Function

A Phase 1 interventional study of DWP16001 in Diabetes Mellitus, Type 2, sponsored by Daewoong Pharmaceutical Co. LTD.. Recruiting at 1 site in Korea, Republic of. Open to participants aged 19 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-04-08.

Sponsored by Daewoong Pharmaceutical Co. LTD. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Apr 2024, 2 years 6 months ago, but the record still lists the study as recruiting.
  • Started Apr 2023; still recruiting 3 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Non-randomized
Ages
19 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 15 studies testing enavogliflozin in Diabetes Mellitus, Type 2 — 7 open to participants now, 8 under way, 4 of them phase 3. Enavogliflozin · Diabetes Mellitus, Type 2.

Planned enrollment
15th of 15
24 · median 140
Started
2023
with 3 others
Phase 1
3 of 15
1 open now
Registered
10th of 15
by date
Lead sponsor
12 of 15
Daewoong Pharmaceutical Co. LTD.

Among the 15 studies testing enavogliflozin in Diabetes Mellitus, Type 2, this one is the 15th largest by planned enrollment, is one of 4 that started in 2023, is one of 3 in phase 1, and was the 10th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

7 of the 15 studies testing enavogliflozin in Diabetes Mellitus, Type 2 are open now, in 1 country. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Where they have run

About enavogliflozin

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 19 Years to 80 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies testing enavogliflozin in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

This study aims to evaluate the pharmacokinetics, pharmacodynamics, safety, and tolerability of DWP16001 in subjects with hepatic impairment compared with subjects with normal hepatic function.

Read the detailed description

The study design is An open-label, multi-center, parallel, single oral dose study.

03

Conditions studied

  • Diabetes Mellitus, Type 2
04

Who can participate

Ages eligible
19 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. A person who has decided to participate voluntarily and agreed in writing prior to the screening procedure after understanding the detailed explanation of this clinical trial.
  2. A person who is 19 years of age or more and under 80 years of age at the time of screening.
  3. Those with a weight of 45.0 kg or more and 90.0 kg or less and a (BMI) of 18.0 kg/m2 or more and 30.0 kg/m2 or less.

Exclusion criteria

Exclusion Criteria:

  1. A person who has a history of gastrointestinal diseases (e.g., ulcer, inflammatory bowel disease, acute or chronic pancreatitis, etc.) or gastrointestinal surgery (except simple appendectomy or hernia surgery) that may affect the absorption of DWP16001.
  2. Those who are hypersensitive to drugs and other drugs (aspirin, antibiotics, etc.) including the SGLT2 inhibitor family or who have a history of reaction.
  3. Serum Cr >1.5mg/dL or (CKD-EPI Cr) \<60mL/min/1.73m2
  4. Those who have used SGLT2 inhibitor family drugs within two weeks of the scheduled date of administration of DWP16001.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
24 participants (estimated)

Study arms

  • Experimental
    DWP16001 to normal haptic function

    Normal hepatic function

    Drug: DWP16001

  • Experimental
    DWP16001 to Child-Pugh Class A

    Child-Pugh Class A

    Drug: DWP16001

  • Experimental
    DWP16001 to Child-Pugh Class B

    Child-Pugh Class B

    Drug: DWP16001

Interventions

  • 0.3mg

    Also known as: DWP16001 0.3mg

06

What researchers measure

Primary outcomes

  1. Cmax of DWP16001

    Cmax of DWP16001

    Time frame: 0 to 48 hours

  2. AUClast of DWP16001

    AUClast of DWP16001

    Time frame: 0 to 48 hours

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2023 (actual). Primary completion is estimated for Apr 2024, 12 months after the start.

Of 453 industry-sponsored phase 1 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 11. This study's planned 12 months is above that.

Counting every sponsor, half of 515 studies reached it within 6 months; a quarter within 2 and three quarters within 14.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 8, 2023
First posted
Feb 28, 2023
StartActual
Apr 13, 2023
Primary completionEst.
Apr 30, 2024
CompletionEst.
Apr 30, 2024
Last update
Apr 8, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 8, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05747664
Responsible party
Sponsor
First posted
Feb 28, 2023
Start date
Apr 13, 2023
Primary completion
Apr 30, 2024 (estimated)
Completion
Apr 30, 2024 (estimated)
Last update
Apr 8, 2024

Study contacts

Younghee Kim
Contact
2210285@daewoong.co.kr
82-10-5768-9733

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Enavogliflozin

Start the discussion